These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21309182)

  • 1. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infectious risks of immunomodulating therapies in rheumatology].
    Van Delden C
    Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
    Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
    Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 9. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
    de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
    Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk?
    Makkuni D; Kent R; Watts R; Clunie G
    Rheumatology (Oxford); 2006 Feb; 45(2):237-8. PubMed ID: 16377730
    [No Abstract]   [Full Text] [Related]  

  • 11. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal vaccination for RA patients on TNF-alpha antagonists.
    Wright SA; Taggart AJ
    Rheumatology (Oxford); 2004 Apr; 43(4):523. PubMed ID: 15024137
    [No Abstract]   [Full Text] [Related]  

  • 13. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 14. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.
    Wolfe F; Michaud K; Dewitt EM
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii13-ii17. PubMed ID: 15479864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
    Calabrese LH; Zein N; Vassilopoulos D
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii18-ii24. PubMed ID: 15479865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis associated with therapy against tumor necrosis factor alpha.
    Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
    Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections and anti-tumor necrosis factor alpha therapy.
    Ellerin T; Rubin RH; Weinblatt ME
    Arthritis Rheum; 2003 Nov; 48(11):3013-22. PubMed ID: 14613261
    [No Abstract]   [Full Text] [Related]  

  • 19. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy.
    Winthrop KL; Furst DE
    Ann Rheum Dis; 2010 Oct; 69(10):1735-7. PubMed ID: 20858622
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.